Special Counsel Finds US FDA’s Dismissal Of Inspection Concerns Unreasonable
Executive Summary
Agency biologics investigator questioned site classification downgrades and belated response to Merck & Co. plant informant’s concerns.
You may also be interested in...
The Quality Lowdown: The Warning Letter Monsoons That Might Follow The Inspection Drought
Selective whistleblower allegations, investigative reports hint at drug GMP issues awaiting US FDA inspection resumption; GSK sotrovimab EUA gets root cause provision; API GMP compliance work acknowledged; Aziyo recalls bone matrix associated with tuberculosis outbreak, and other matters in this latest update.
Merck’s COVID Manufacturing Deal With US Government Goes Well Beyond J&J Vaccine
‘Wartime’ contract with BARDA will fund up to $268.8m in production site upgrades so Merck can also produce other COVID-19 vaccines and therapeutics as needed.
Why Data Integrity Concerns Led Fresenius To Back Away From Akorn Deal
Tipped off by whistleblower, Fresenius reviewed data integrity audits that led it to back away from plans to acquire Akorn, firm tells court. It’s a case with lessons for any pharmaceutical company that wants to ensure its own data integrity – and that of its business partners.